Foundation Medicine
FoundationOne CDx and FoundationOne Liquid CDx carry stacked FDA companion-diagnostic approvals (Tepmetko/tepotinib in MET exon-14-skipping NSCLC; Talzenna/talazoparib with Xtandi/enzalutamide in HRR-mutated mCRPC; Akeega/niraparib-abiraterone in BRCA-positive mCRPC),…
- Country
- United States
Commercial
FoundationOne CDx / Liquid CDx / MRD
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Liquid biopsy & ctDNA diagnostics | diagnostics-medtech | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.